Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 10:14:25158414221125697.
doi: 10.1177/25158414221125697. eCollection 2022 Jan-Dec.

A comparison of iStent combined with phacoemulsification and endocyclophotocoagulation (ICE2) with the PreserFlo MicroShunt and XEN-45 implants

Umair Qidwai  1 , Lee Jones  1   2 , Gokulan Ratnarajan  3
Affiliations

A comparison of iStent combined with phacoemulsification and endocyclophotocoagulation (ICE2) with the PreserFlo MicroShunt and XEN-45 implants

Umair Qidwai et al. Ther Adv Ophthalmol. .

Abstract

Background: Minimally invasive glaucoma surgery (MIGS), including minimally invasive bleb surgery (MIBS), is a rapidly evolving area of research and clinical interest in ophthalmology. The growing number of devices has necessitated evaluations to identify subtle differences in outcomes between treatments.

Objectives: To compare clinical effectiveness and safety outcomes of iStent combined with endoscopic cyclophotocoagulation (ICE2) with bleb forming PreserFlo MicroShunt (PMS) and XEN-45 gel implant in a 24-month retrospective review.

Design: A retrospective review of patient records.

Methods: We compared outcomes of 247 patients undergoing one of three glaucoma procedures (ICE2 = 162; PMS = 48; XEN-45 = 37) at a single facility in the United Kingdom. Clinical records were reviewed retrospectively between July 2016 and May 2020. Pairwise comparisons and within group analyses were performed to assess intraocular pressure (IOP), best-corrected LogMAR visual acuity (BCVA), the Humphrey visual fields and antiglaucoma medication outcomes across the three treatment groups.

Results: No statistically significantly differences in IOP between the groups at day 7, 6 months, 12 months and 24 months. PMS had statistically significantly change in IOP between baseline and day 7 compared with ICE2 (p = 0.003). BCVA was statistically significant different at 24 months between the ICE2 compared with PMS group (0.12 versus 0.33 LogMAR; p = 0.002). PMS group achieved the largest decline in medication usage between baseline a 24-month follow-up (2.9 versus 0.9; p < 0.001), with no statistically significant difference in the number of antiglaucoma medications being used between groups at 24 months. Postoperative complications in all three groups were transient and could be resolved with office-based interventions.

Conclusion: Real-world outcomes after 24 months were similar between patients undergoing MIGS and MIBS procedures.

Keywords: clinical effectiveness; minimally invasive glaucoma surgery; safety.

PubMed Disclaimer

Conflict of interest statement

The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Figures

Figure 1.
Figure 1.
Average and standard deviation IOP measurements (mmHg) across treatment groups over the 24-month study period. ICE2, iStent combined with endoscopic cyclophotocoagulation; IOP, intraocular pressure; PMS, PreserFlo MicroShunt.
Figure 2.
Figure 2.
Average and standard deviation BCVA measurements (LogMAR) across treatment groups over the 24-month study period.
See this image and copyright information in PMC

References

    1. Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014; 121: 2081–2090. - PubMed
    1. Ramli N, Supramaniam G, Samsudin A, et al.. Ocular surface disease in glaucoma: effect of polypharmacy and preservatives. Optom Vis Sci 2015; 92: e222–e226. - PubMed
    1. Mylla Boso AL, Gasperi E, Fernandes L, et al.. Impact of ocular surface disease treatment in patients with glaucoma. Clin Ophthalmol 2020; 14: 103–111. - PMC - PubMed
    1. Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol 2012; 153: 1–9.e2. - PubMed
    1. Baudouin C, Labbé A, Liang H, et al.. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 2010; 29: 312–334. - PubMed

LinkOut - more resources